Medicare Claims for Duplicate Laboratory Services Continue to Be Denied
The Centers for Medicare & Medicaid Services (CMS) says it will continue to deny claims for duplicate laboratory services unless the tests are deemed...
1 min read
Oral arguments will be heard on Feb. 19 in the lawsuit concerning federal oversight of laboratory-developed tests (LDTs).
On Jan. 23, the U.S. District Court in Eastern Texas granted a motion for oral arguments to be heard. The plaintiffs -- the American Clinical Laboratory Association and Association for Molecular Pathology -- along with the defendant, the U.S. Food and Drug Administration, submitted a request on Jan. 17 for an oral hearing on their cross-motions for summary judgment.
In the written request, the plaintiffs explained they are seeking an oral hearing “because this case is being decided on dispositive cross-motions and involves important legal issues arising from a major new FDA rule,” while the defendants intend to begin enforcing the rule at issue on May 6, 2025.
The final rule would regulate LDTs as medical devices under the Food, Drug, and Cosmetics Act. The plaintiffs’ lawsuits were consolidated on Sept. 9, 2024, with the shared objective to challenge the statutory validity and ultimately achieve vacatur of the final rule. The FDA filed its closing brief in the case on Dec. 23, reasserting its “unambiguous statutory authority” to regulate LDTs as “diagnostic ‘apparatuses’ or ‘contrivances’ made up of physical components that work together to produce a test result.”
Sources:
https://www.cap.org/advocacy/latest-news-and-practice-data/january-28-2025#story1
https://documents.cap.org/documents/oral-argument-request.pdf
https://www.amp.org/AMP/assets/File/advocacy/DOJ_ClosingBrief_12_23_2024.pdf?pass=71
CAP Submits Comments on Proposed 2027 Medicare Physician Fee Schedule
The College of American Pathologists (CAP) submitted comments to the proposed 2027 Medicare Physician Fee Schedule (PFS), addressing proposals that...
CMS Announces Phased-In Reduction of Medicare Payment Rates for Lab Services
The Centers for Medicare & Medicaid Services (CMS) plans to reduce preliminary Medicare payment rates for laboratory services.